Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects



Rating:

Share or cite this content

Citations should be made in the following way:
M. Wencker, M. Schulte, J. Seitz, G. Klein, T. Meyer (Frankfurt, Gauting, Germany; NC, United States Of America). Regional deposition of ^99mTc-labelled alpha-1 antitrypsin (AAT) in patients with alpha-1 antitrypsin deficiency and cystic fibrosis (CF) compared with healthy volunteers. Eur Respir J 2007; 30: Suppl. 51, 3770

Member's Comments

No comment yet.

Related content which might interest you: Alpha 1 antitrypsin (A1AT) deficiency among patients with cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 501s Year: 2003 Intra-epithelial polymerization, accumulation and secretion of alpha1 antitrypsin (AAT) Z polymers in the lung of patients with alpha-1 antitrypsin deficiency (AATD) Source: Annual Congress 2010 - Epithelial cell biology Year: 2010 Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD). Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases Year: 2021 Alpha-1 antitrypsin (AAT) polymerization in alveolar macrophages of AAT deficient individuals and in smokers. Source: International Congress 2017 – New Mechanistic Findings in COPD Year: 2017 The results of alpha-1 antitrypsine (AAT) phenotyping in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 260s Year: 2002 Exercise intolerance and lung emphysema in alpha-1 antitrypsin deficiency (AATD) Source: Annual Congress 2010 - Exercise in COPD Year: 2010 Functional alterations of small airways in patients with alpha-1 antitrypsin deficiency (AATD) in a longitudinal study Source: Eur Respir J 2005; 26: Suppl. 49, 361s Year: 2005 Screening for alpha-1 antitrypsin deficiency in Polish lung or liver disease patients Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 Characterisation of alpha-1 antitrypsin protein expression and secretion in natural killer cells from healthy volunteers and alpha-1 antitrypsin deficiency patients Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 A high purity alpha-1 antitrypsin (AAT) from human plasma, TAL6004 Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Alpha-1 antitrypsin (AAT) and alpha-2 macroglobulin (AMG) levels according to the stages and histological types in lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Lung function in relation to emphysema development in alpha-1 antitrypsin deficiency Source: International Congress 2019 – Insights into physiological diagnostic services Year: 2019 Alpha-1 antitrypsin deficiency in patients with COPD/emphysema, bronchiectasis and asthma Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases Year: 2020 COPD in individuals with the PiMZ alpha-1 antitrypsin genotype Source: Eur Respir Rev, 26 (146) 170068; 10.1183/16000617.0068-2017 Year: 2017 Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD) Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 Alveolar nitric oxide correlates with lung volumes in patients with emphysema and Alpha-1 antitrypsin deficiency (AATD) Source: Eur Respir J 2006; 28: Suppl. 50, 223s Year: 2006 Clinical features of alpha one antitrypsin deficiency in non cystic fibrosis bronchiectasis Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012